For: | Du ZQ, Zhao JZ, Dong J, Bi JB, Ren YF, Zhang J, Khalid B, Wu Z, Lv Y, Zhang XF, Wu RQ. Effect of low-dose aspirin administration on long-term survival of cirrhotic patients after splenectomy: A retrospective single-center study. World J Gastroenterol 2019; 25(28): 3798-3807 [PMID: 31391774 DOI: 10.3748/wjg.v25.i28.3798] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v25/i28/3798.htm |
Number | Citing Articles |
1 |
Xun Qiu, Fengqiang Gao, Kai Wang, Zhensheng Zhang, Chuxiao Shao, Xiao Xu. Aspirin in hepatocellular carcinoma: Is it an out-of-date or promising treatment?. iLIVER 2022; 1(1): 55 doi: 10.1016/j.iliver.2022.03.003
|
2 |
Lun-Jie Yan, Sheng-Yu Yao, Hai-Chao Li, Guang-Xiao Meng, Kai-Xuan Liu, Zi-Niu Ding, Jian-Guo Hong, Zhi-Qiang Chen, Zhao-Ru Dong, Tao Li. Efficacy and Safety of Aspirin for Prevention of Hepatocellular Carcinoma: An Updated Meta-analysis. Journal of Clinical and Translational Hepatology 2022; 10(5): 835 doi: 10.14218/JCTH.2021.00257
|
3 |
Yikai Wang, Muqi Wang, Chenrui Liu, Wenjun Wang, Juanjuan Shi, Shuangsuo Dang. Aspirin Use and the Risk of Hepatocellular Carcinoma. Journal of Clinical Gastroenterology 2022; 56(7): e293 doi: 10.1097/MCG.0000000000001693
|
4 |
Hongda Ding, Yingshi Zhang, Liang Zhao, Si Wu, Junpeng Liu, Caibin Wang, Tong Pei, Yang Su. What intervention regimen is most effective prevention for Portal venous system thrombosis after splenectomy in cirrhotics patients with Portal hypertension? Systematic review and network meta-analysis. Pharmacological Research 2020; 157: 104825 doi: 10.1016/j.phrs.2020.104825
|
5 |
Tracey G. Simon, Andrew T. Chan. Lifestyle and Environmental Approaches for the Primary Prevention of Hepatocellular Carcinoma. Clinics in Liver Disease 2020; 24(4): 549 doi: 10.1016/j.cld.2020.06.002
|
6 |
Xueliang Zhou, Tengfei Zhang, Yali Sun, Chunwei Li, Xianfei Ding, Yanhui Zhu, Lifeng Li, Zhirui Fan. Systematic Review and Meta-analysis: Association of Aspirin With Incidence of Hepatocellular Carcinoma. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.764854
|
7 |
Regina Zi Hwei Tan, Ian Lockart, Christina Abdel Shaheed, Mark Danta. Systematic review with meta‐analysis: The effects of non‐steroidal anti‐inflammatory drugs and anti‐platelet therapy on the incidence and recurrence of hepatocellular carcinoma. Alimentary Pharmacology & Therapeutics 2021; 54(4): 356 doi: 10.1111/apt.16515
|
8 |
Wenfeng Zhu, Xiaowen Wang, Yun Lv, Haoqi Chen, Xiaolong Chen, Xuejiao Li, Shuguang Zhu, Zexin Lin, Genshu Wang. Comparison of long-term outcomes of splenectomy with periesophagogastric devascularization and transjugular intrahepatic portosystemic shunt in treating cirrhotic portal hypertension patients with recurrent variceal bleeding. Langenbeck's Archives of Surgery 2023; 408(1) doi: 10.1007/s00423-023-02933-1
|
9 |
Mengshi Yi, Xi Feng, Wei Peng, Fei Teng, Youyin Tang, Zheyu Chen. Aspirin for the prevention of hepatocellular carcinoma: an updated meta-analysis with particular focus on patients with chronic liver disease. European Journal of Clinical Pharmacology 2022; 78(4): 647 doi: 10.1007/s00228-021-03247-1
|
10 |
Daniel Eckhardt, Georg F. Weber. Perioperative Medizin für die Allgemein- und Viszeralchirurgie. 2024; : 349 doi: 10.1007/978-3-662-64404-1_38
|
11 |
Pamela Czajka, Adam Przybyłkowski, Anna Nowak, Marek Postula, Marta Wolska, Dagmara Mirowska-Guzel, Anna Czlonkowska, Ceren Eyileten. Antiplatelet drugs and liver fibrosis. Platelets 2022; 33(2): 219 doi: 10.1080/09537104.2021.1883574
|
12 |
Yuwei Liu, Tianqi Ren, Xiaotong Xu, Jinglan Jin. Association of aspirin and nonaspirin NSAIDs therapy with the incidence risk of hepatocellular carcinoma: a systematic review and meta-analysis on cohort studies. European Journal of Cancer Prevention 2022; 31(1): 35 doi: 10.1097/CEJ.0000000000000663
|
13 |
Jin Lin Tan, Sandeep Sidhu-Brar, Richard Woodman, Mohamed Asif Chinnaratha. Regular Aspirin Use Is Associated with a Reduced Risk of Hepatocellular Carcinoma (HCC) in Chronic Liver Disease: a Systematic Review and Meta-analysis. Journal of Gastrointestinal Cancer 2023; 54(2): 325 doi: 10.1007/s12029-022-00842-y
|
14 |
Jonathan Abdelmalak, Natassia Tan, Danny Con, Guy Eslick, Ammar Majeed, William Kemp, Stuart K. Roberts. The Effect of Aspirin Use on Incident Hepatocellular Carcinoma—An Updated Systematic Review and Meta-Analysis. Cancers 2023; 15(13): 3518 doi: 10.3390/cancers15133518
|
15 |
Pierluigi Ramadori, Thomas Klag, Nisar Peter Malek, Mathias Heikenwalder. Platelets in chronic liver disease, from bench to bedside. JHEP Reports 2019; 1(6): 448 doi: 10.1016/j.jhepr.2019.10.001
|
16 |
Myung Ji Goh, Dong Hyun Sinn. Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?. Clinical and Molecular Hepatology 2022; 28(3): 380 doi: 10.3350/cmh.2021.0366
|
17 |
Taha Ahmed, Alla Y. Grigorian, Adrian W. Messerli. Management of Acute Coronary Syndrome in Patients with Liver Cirrhosis. American Journal of Cardiovascular Drugs 2022; 22(1): 55 doi: 10.1007/s40256-021-00478-6
|
18 |
Shaodi Ma, Guangbo Qu, Chenyu Sun, Haixia Liu, Yuemeng Jiang, Ning Li, Birong Wu, Juan Gao, Linya Feng, Peng Xie, Weihang Xia, Na Hyun Kim, Scott Lowe, Rachel Bentley, Yike Zhu, Qin Zhou, Yehuan Sun. Does aspirin reduce the incidence, recurrence, and mortality of hepatocellular carcinoma? A GRADE-assessed systematic review and dose–response meta-analysis. European Journal of Clinical Pharmacology 2023; 79(1): 39 doi: 10.1007/s00228-022-03414-y
|